Longer Duration of Treatment with ICIs Associated with a Higher Rate of Complete Response Among Patients with MMRd Cancers By Ogkologos - March 5, 2025 710 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a systematic review of published studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR 30-Year-Old Mom of 7 With Terminal Breast Cancer Is Gifted Dream... January 10, 2020 Silence Speaks Volumes June 16, 2020 Surgical Technique Helps Keep Breast Cancer Patients from Going Under the... September 26, 2019 What Are Multi-Cancer Early Detection Tests and How Might They Impact... October 25, 2022 Load more HOT NEWS Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant,... New on NCI’s Websites for September 2020 Clinical Trials in Genitourinary Cancers: TALAPRO-2, KEYNOTE-905, and COSMIC-313 New on NCI’s Websites for December 2020
